PL1951661T3 - Antagoniści receptora glukagonu, wytwarzanie i terapeutyczne zastosowania - Google Patents

Antagoniści receptora glukagonu, wytwarzanie i terapeutyczne zastosowania

Info

Publication number
PL1951661T3
PL1951661T3 PL06850109T PL06850109T PL1951661T3 PL 1951661 T3 PL1951661 T3 PL 1951661T3 PL 06850109 T PL06850109 T PL 06850109T PL 06850109 T PL06850109 T PL 06850109T PL 1951661 T3 PL1951661 T3 PL 1951661T3
Authority
PL
Poland
Prior art keywords
preparation
receptor antagonists
therapeutic uses
glucagon receptor
glucagon
Prior art date
Application number
PL06850109T
Other languages
English (en)
Polish (pl)
Inventor
Scott Eugene Conner
Jianke Li
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1951661T3 publication Critical patent/PL1951661T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL06850109T 2005-11-17 2006-11-07 Antagoniści receptora glukagonu, wytwarzanie i terapeutyczne zastosowania PL1951661T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73762705P 2005-11-17 2005-11-17
PCT/US2006/060586 WO2007106181A2 (en) 2005-11-17 2006-11-07 Glucagon receptor antagonists, preparation and therapeutic uses
EP06850109A EP1951661B1 (en) 2005-11-17 2006-11-07 Glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
PL1951661T3 true PL1951661T3 (pl) 2012-12-31

Family

ID=38474434

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06850109T PL1951661T3 (pl) 2005-11-17 2006-11-07 Antagoniści receptora glukagonu, wytwarzanie i terapeutyczne zastosowania

Country Status (14)

Country Link
US (1) US7696248B2 (enExample)
EP (1) EP1951661B1 (enExample)
JP (1) JP5107253B2 (enExample)
CN (1) CN101309895B (enExample)
AU (1) AU2006340002B2 (enExample)
BR (1) BRPI0618349A2 (enExample)
CA (1) CA2629348C (enExample)
CY (1) CY1113159T1 (enExample)
DK (1) DK1951661T3 (enExample)
ES (1) ES2391109T3 (enExample)
PL (1) PL1951661T3 (enExample)
PT (1) PT1951661E (enExample)
SI (1) SI1951661T1 (enExample)
WO (1) WO2007106181A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1758853E (pt) * 2004-06-14 2010-03-02 Lilly Co Eli Antagonistas do receptor de glucagon, sua preparação e usos terapêuticos
KR101538810B1 (ko) 2007-02-09 2015-07-22 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5465658B2 (ja) * 2008-03-05 2014-04-09 武田薬品工業株式会社 複素環化合物
BRPI0918004B8 (pt) 2008-08-13 2021-05-25 Metabasis Therapeutics Inc compostos antagonistas e agonistas inversos de receptores de glucagon, composição farmacêutica e uso dos compostos
JP2012504630A (ja) 2008-10-03 2012-02-23 シェーリング コーポレイション グルカゴン受容体アンタゴニストとしてのスピロイミダゾロン誘導体
CL2009001796A1 (es) * 2009-02-06 2011-09-16 Takeda Pharmaceuticals Co Compuestos derivados de heteroarilo-(benceno/heteroarilo) fusionados con actividad antagonista de glucagon; composicion farmaceutica; y su uso para suprimir la produccion de azucar y para la terapia o el tratamiento de la diabetes.
EP2480077B1 (en) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
KR101506829B1 (ko) 2010-12-23 2015-03-30 화이자 인코포레이티드 글루카곤 수용체 조절제
KR101585840B1 (ko) * 2011-02-08 2016-01-15 화이자 인코포레이티드 글루카곤 수용체 조절자
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
ES2544104T3 (es) * 2011-05-23 2015-08-27 Janssen Pharmaceutica, N.V. Derivados de bifenilo útiles como antagonistas del receptor glucagón
WO2012162407A1 (en) * 2011-05-23 2012-11-29 Janssen Pharmaceutica Nv Picolinamido - propanoic acid derivatives useful as glucagon receptor antagonists
BR112014000288A2 (pt) 2011-07-22 2017-01-10 Pfizer moduladores do receptor de glucagon de quinolinila
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JPWO2013147026A1 (ja) 2012-03-29 2015-12-14 武田薬品工業株式会社 芳香環化合物
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
JP2016052300A (ja) * 2014-09-03 2016-04-14 日立化成株式会社 生体物質捕獲システム
US12208071B2 (en) 2018-02-13 2025-01-28 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
CN1356977A (zh) * 1999-05-17 2002-07-03 诺沃挪第克公司 胰高血糖素拮抗剂/反向激动剂
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
JP2005511683A (ja) 2001-12-03 2005-04-28 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
JP2006500325A (ja) 2002-06-27 2006-01-05 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
AU2003291959A1 (en) 2002-12-20 2004-07-14 Novo Nordisk A/S Novel glucagon antagonists
JP2008533200A (ja) 2005-03-21 2008-08-21 メルク エンド カムパニー インコーポレーテッド 置換アリールおよびヘテロアリール誘導体、かかる化合物を含有する組成物および使用法

Also Published As

Publication number Publication date
CA2629348C (en) 2013-08-13
ES2391109T3 (es) 2012-11-21
AU2006340002B2 (en) 2011-12-22
DK1951661T3 (da) 2012-09-03
EP1951661B1 (en) 2012-08-08
WO2007106181A2 (en) 2007-09-20
CY1113159T1 (el) 2016-04-13
JP2009519226A (ja) 2009-05-14
CN101309895B (zh) 2012-10-03
US20080300308A1 (en) 2008-12-04
AU2006340002A1 (en) 2007-09-20
EP1951661A2 (en) 2008-08-06
US7696248B2 (en) 2010-04-13
CA2629348A1 (en) 2007-09-20
JP5107253B2 (ja) 2012-12-26
PT1951661E (pt) 2012-09-19
BRPI0618349A2 (pt) 2011-08-23
WO2007106181A3 (en) 2007-12-06
SI1951661T1 (sl) 2012-11-30
CN101309895A (zh) 2008-11-19

Similar Documents

Publication Publication Date Title
SI1951661T1 (sl) Antagonisti glukagonskega receptorja priprava interapevtske uporabe
SI1951658T1 (sl) Antagonisti glukagonskega receptorja priprava interapevtska uporaba
IL186601A0 (en) Npy antagonists, preparation and use
TWI346553B (en) Chemokine receptor antagonists
IL180682A0 (en) N-hydroxamide derivatives, their preparation and use
IL190686A0 (en) Il-21 receptor antagonists
IL201262A0 (en) Gonadotropin-releasing hormone receptor antagonists and uses thereof
IL180284A0 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
TWI341198B (en) Hydroisoindoline tachykinin receptor antagonists
IL179462A0 (en) Use of the receptor gpr86
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
EP1812008A4 (en) ANTAGONISTS OF THE IL-8 RECEPTOR
IL190519A0 (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
EP1806147A4 (en) USE OF IMMUNOSUPPRESSIVE RECEPTOR
IL178622A0 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
PL1951659T3 (pl) Antagoniści receptora glukagonu, wytwarzanie i zastosowania terapeutyczne
GB0414798D0 (en) Receptor
ZA200605574B (en) Hydroisoindoline tachykinin receptor antagonists
GB0525029D0 (en) Receptor Antagonist
HK1111693A (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
GB0413872D0 (en) Receptor
IL190836A0 (en) Cxc-chemokine antagonists, their preparation and use
GB0404584D0 (en) Receptor
GB0417119D0 (en) Receptor